Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives.

Details

Serval ID
serval:BIB_3F3EE764A453
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives.
Journal
Frontiers in cell and developmental biology
Author(s)
Faes S., Demartines N., Dormond O.
ISSN
2296-634X (Print)
ISSN-L
2296-634X
Publication state
Published
Issued date
2021
Peer-reviewed
Oui
Volume
9
Pages
636037
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Several elements highlight the importance of the mechanistic target of rapamycin (mTOR) in the biology of renal cell carcinoma (RCC). mTOR signaling pathway is indeed frequently activated in RCC, inducing cancer cell proliferation and survival. In addition, mTOR promotes tumor angiogenesis and regulates the expression of hypoxia-inducible factors that play an important role in a subset of RCC. Despite mTOR protumorigenic effects, mTOR inhibitors have failed to provide long-lasting anticancer benefits in RCC patients, highlighting the need to readdress their role in the treatment of RCC. This review aims to present the rationale and limitations of targeting mTOR in RCC. Future roles of mTOR inhibitors in the treatment of RCC are also discussed, in particular in the context of immunotherapies.
Keywords
HIF-α, angiogenesis, mTOR, rapalogs, renal cell carcinoma
Pubmed
Web of science
Open Access
Yes
Create date
16/04/2021 17:08
Last modification date
20/04/2021 5:34
Usage data